Bioactive Molecules Articles & Analysis: Older
6 news found
CD Formulation, a leading pharmaceutical contract service company, has recently unveiled groundbreaking hydrogel microneedle patch technology aiming at increase the drug loading capacity and enhance drug delivery efficiency. The new technology represents a significant advancement in the field of transdermal drug delivery. The hydrogel microneedle patch consists of a patch with tiny microneedles ...
Microsphere formulation has been highlighted as a promising dosage form in clinical practice due to its ability to significantly improve patient convenience and compliance. As a trustworthy partner in the field of pharmaceutical formulation, CD Formulation has newly introduced a range of raw materials for the production of microspheres and microneedles, which are highly expected to advance ...
The US-based chemical supplier Alfa Chemistry recently announced the availability of a range of bioactive molecules for scientific research, including activators, agonists, antagonists, and inhibitors. Bioactive molecules are compounds that can interact with biological systems, such as proteins, enzymes, and the human body, and produce a physiological response. They play a crucial role in the ...
CD Genomics, a leading provider of transcriptomics sequencing solutions, is pleased to announce the launch of its Exosomal RNA Sequencing service. This innovative service is set to provide researchers with comprehensive and accurate analysis of exosomal RNA, facilitating a deeper understanding of their functional significance in various biological processes. Exosomes, small extracellular ...
Kallyope, a leading biotechnology company focused on identifying and developing therapeutics targeting the gut-brain axis, and Brightseed, creators of Forager®, a pioneering artificial intelligence platform that illuminates the connections between nature and human health, have entered a strategic research collaboration to screen plant compounds to identify and validate active agents that can ...
TISSIUM, a privately-owned life science company developing fullysynthetic, biomorphic programmable polymers, announced today it has been awarded 2.2M€ in financing that will accelerate its development of a drug-eluting tissue adhesive to address the unmet needs of Chronic Rhinosinusitis (CRS) patients. The funding comes from the Investments for the Future program (Programme ...
ByTISSIUM